MRNS - Earnings announcements

ZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35 million Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) with topline data expected in the first half of Q4 2024 Expanded ZTALMY global footprint with activation of managed access programs for MENA, Russia and Canada with upcoming commercial launches anticipated in Europe and China Succeeded in post-grant review challenge of Ovid Therapeutics' U.S. Patent 11,395,817 for IV ganaxolone in the treatment of status epilept

Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will host a conference call at 8:30 a.m. E.T. on August 13, 2024, to provide a business update and discuss financial results. Tuesday, August 13, 8:30 a.m. E.T. Domestic: (877) 405-1242 International: (201) 389-0852 Webcast Registration: Click Here An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/e

Conference Call and Webcast March 20 at 8:00 AM Eastern Time / 7:00 AM Central Time ReMEDy2 Clinical Site Activation Commenced in December 2023 Strengthened Management Team with Lorianne Masuoka, M.D., as Chief Medical Officer $53 Million Cash with Runway to 2026 DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023. Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full

Phase 3 RAISE trial interim analysis enrollment target achieved with Data Monitoring Committee (DMC) review scheduled and topline results expected in first half of Q2 2024 Phase 3 TrustTSC trial approximately 85% enrolled with topline data now expected in first half of Q4 2024 ZTALMY® (ganaxolone) net product revenue of $6.6 million for Q4 2023 and $19.6 million for the full year ended December 31, 2023 Full year 2024 U.S. ZTALMY net product revenue guidance of between $32 and $34 million Cash runway projected into Q4 2024 with cash, cash equivalents and short-term investments of $150.3 million as of December 31, 2023 Marinus to host conference call today at 4:30 p.m. ET

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 on March 5, 2024. The Company will host a conference call at 4:30 p.m. E.T. on March 5, 2024, to provide a business update and discuss financial results. Tuesday, March 5, 4:30 p.m. E.T. Domestic: (888) 550-5280 International: (646) 960-0813 Webcast Registration: https://events.q4inc.com/attendee/513453609 Conference ID: 2696394 An archived version of the call will be available approximately two hours after the com

ZTALMY® (ganaxolone) Q3 net product revenue of $5.4 million; 2023 net product revenue guidance increased to between $18.5 and $19 million Over 75% of patients required for the interim analysis are now enrolled in the Phase 3 RAISE trial in refractory status epilepticus; if the trial meets pre-defined stopping criteria at the interim analysis, topline data now anticipated Q2 2024 Initiated the Marinus Access Program to expand global availability of ZTALMY Cash runway projected into Q4 2024 with cash, cash equivalents and short-term investments of $176.4 million as of September 30, 2023 Marinus to host conference call on November 7, 2023, at 8:30 a.m. ET Marinus Pharmaceutical

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on November 7, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus' website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website. About Marinus Pharmaceuticals  Marinus is a c

ZTALMY® (ganaxolone) second quarter net product revenue of $4.2 million; 2023 net product revenue guidance increased to between $17 and $18.5 million European Commission approved ZTALMY in CDKL5 deficiency disorder Interim analysis for the Phase 3 refractory status epilepticus trial now expected Q1 2024 First patient dosed in MAD trial with second generation ganaxolone formulation New emergency IND dosing paradigm for super refractory status epilepticus showing encouraging initial results Granted a new method of use patent by USPTO for ganaxolone in tuberous sclerosis complex Cash runway expected into second half of 2024 with cash, cash equivalents and short-term investme

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2023 on August 10, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on August 10, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus' website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website. About Marinus Pharmaceuticals Marinus is a commer

ZTALMY® (ganaxolone) first quarter U.S. net product revenue of $3.3 million Now planning to conduct an interim analysis for the Phase 3 refractory status epilepticus trial in the second half of 2023 CHMP opinion for ZTALMY in CDKL5 deficiency disorder expected by end of May; European Medicines Agency communicated that the major objection related to the choice of regulatory starting material has been resolved Phase 3 tuberous sclerosis complex (TSC) trial data now expected mid-2024 Received a notice of allowance from the USPTO for a new method of use patent for ganaxolone in TSC; when granted, the term will run through 2040 Entered exclusive distribution and supply agreement

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2023 on May 11, 2023. The Company will host a conference call at 8:30 a.m. Eastern Time on May 11, 2023. Participants may access the conference call via webcast on the Investors and Media page of Marinus' website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website. About Marinus Pharmaceuticals Marinus is a commercial-s

ZTALMY® U.S. net product revenue of $2.3 million for the fourth quarter of 2022 and $2.9 million for the fiscal year ended December 31, 2022 Company expects ZTALMY U.S. net product revenues of between $15 million and $17 million for the fiscal year ending December 31, 2023 Second generation oral formulation development continues to advance based on encouraging Phase 1 data Actively recruiting Phase 3 clinical trials in refractory status epilepticus and tuberous sclerosis complex; data continues to be expected 2H 2023 and Q1 2024, respectively Phase 2 clinical trial of oral ganaxolone in PCDH-19 published in Epilepsy Research Cash and cash equivalents of $240.6 million as of Decem

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on March 7, 2023. Participants may access the conference call via webcast on the Investor page of Marinus' website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website. About Marinus Pharmaceuticals Marinus is a commercial-stage pha

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ganaxolone data from three abstracts, including one late-breaking abstract, will be presented at the upcoming 2022 American Epilepsy Society (AES) Annual Meeting, which will be held December 2-6, 2022, in Nashville, TN. Marinus will also host a scientific exhibit and investor breakfast event with members of its leadership team to highlight ganaxolone's potential across a range of seizure disorders and discuss its commercial progress and strategy. Presentation Details: Pharmacokinetics of Co-administered Ganaxolone an

Initiated U.S. ZTALMY® (ganaxolone) launch in late July with over 50 completed CDKL5 deficiency disorder prescription enrollment forms; approximately 40% of those patients were on reimbursed therapy by the end of the third quarter ZTALMY generated $0.56 million in net product revenue for the first partial quarter following launch and received positive coverage criteria from over 15 payers representing approximately 70 million lives Actively recruiting Phase 3 clinical trials in refractory status epilepticus and tuberous sclerosis complex; data continues to be expected 2H 2023 and Q1 2024, respectively Cash runway projected to extend into Q1 2024 following sale of Priority Review Vouc

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2022 before the U.S. financial market opens on November 8, 2022. The Company will host a conference call at 8:30 a.m. Eastern Time on November 8, 2022. Participants may access the conference call via webcast on the Investor page of Marinus' website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website. About Marinus Pharm

ZTALMY® can now be prescribed by healthcare professionals in the U.S. Second generation ganaxolone formulation demonstrates encouraging results in Phase 1 study in healthy volunteers and supports further clinical development Marinus' Phase 2 refractory status epilepticus (RSE) trial data published in Epilepsia in June Phase 3 RAISE trial in RSE protocol amendment to expand eligibility criteria to support recruitment expected to be implemented across majority of sites by end of Q3; data readout continues to be expected 2H 2023 First patient dosed and actively screening patients in Phase 3 TrustTSC trial in tuberous sclerosis complex; data anticipated Q1 2024 Completion of sale of

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2022 before the U.S. financial market opens on August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Time on August 11, 2022. Participants may access the conference call via webcast on the Investor page of Marinus' website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website. About Marinus Pharmaceuti

ZTALMY® (ganaxolone) U.S. commercial launch on track for July 2022 Phase 3 RAISE trial in refractory status epilepticus continues to advance with resumption of screening and recruitment; data readout expected second half 2023 Site activations advance in Phase 3 TrustTSC trial in tuberous sclerosis complex; topline data anticipated first quarter 2024 Patient dosing underway for Phase 1 trial of ganaxolone second generation formulation; topline data on track for mid-2022 readout Continue to strengthen cash position with Oaktree Capital drawdown and expectation to monetize priority review voucher Marinus to host conference call today at 4:05 p.m. ET Marinus Pharmaceuticals, Inc. (

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2022 after the market closes on May 12, 2022. The Company will host a conference call at 4:00 p.m. ET on May 12, 2022 to provide a business update and discuss the financial results. Thursday, May 12: 4:00 p.m. Eastern Time Domestic: (888) 550-5280 International: (646) 960-0813 Webcast Link: https://events.q4inc.com/attendee/993378901 Conference ID: 2696394 About Marinus Pharmaceuticals Marinus is a pharmaceutical company dedicated t

Received FDA approval of ZTALMY® (ganaxolone) for the treatment of seizures associated with CDKL5 deficiency disorder; first approved treatment for this rare form of genetic epilepsy Awarded a Rare Pediatric Disease Priority Review Voucher by the FDA Eligible for an additional $30 million of funding under the existing Oaktree Capital Management, L.P. credit agreement Patient screening commenced for Phase 3 TrustTSC trial in tuberous sclerosis complex Resupply of clinical trial materials has been moved up to May 2022 for Phase 3 RAISE trial in refractory status epilepticus Marinus to host conference call today at 8:00 a.m. ET / 5 a.m. PT Marinus Pharmaceuticals, Inc. (NASDAQ:MRN

First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older1 ZTALMY significantly reduced major motor seizure frequency in CDD patients in the pivotal Marigold trial Rare Pediatric Disease Priority Review Voucher awarded to Marinus Pharmaceuticals by the FDA Marinus to host conference call March 21, at 8:00 a.m. ET Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved ZTALMY® (ganaxolone) oral suspension for the treatment of seizures a

RAISE trial delayed due to impacts from COVID-19 variant and recent interruption in clinical supply material Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that due to the impact of the COVID-19 Omicron variant on hospital resources and an unexpected interruption of clinical supply material associated with IV ganaxolone, the RAISE, Phase 3, double-blind placebo-controlled trial for the treatment of status epilepticus, is now expected to be completed in the second half of 2023. Marinus has temporarily paused the RAISE trial after routine monitoring of stability batches

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced plans to provide a business update and preliminary financial results for the fourth quarter and fiscal year ended December 31, 2021 before the market opens on March 21, 2022. The company will host a conference call at 8:00 a.m. Eastern Time on March 21, 2022, to provide a business update and discuss the financial results. Monday, March 21, 8:00 a.m. ET Domestic: +1 (888) 550-5280 International: (646) 960-0813 Webcast Link: https://events.q4inc.com/attendee/991025183 Conference ID: 2696394 About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced plans to release financial results for the third quarter ended September 30, 2021 before the market opens on November 9, 2021. The company will host a conference call at 8:30 a.m. Eastern Time on November 9, 2021, to provide a business update and discuss the financial results. Tuesday, November 9, 8:30 a.m. ET Domestic: +1 833-979-2765 International: (343) 761-2590 Webcast Link: https://event.on24.com/wcc/r/3435370/D4A161A628859FC2957F63CBDDD69D3A Conference ID: 6362837 About Marinus Pharmaceuticals Marinus Pharmac

Primary endpoint showed a median 16.6% reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23) Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results 25.2% reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients Meaningful 50% responder rates in subgroups of highly refractory seizure patients on concomitant medications cannabidiol (n=12) or everolimus (n=11) Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021 U.S. Food and Drug Administration (FDA) has granted orphan drug des

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced plans to release financial results for the second quarter ended June 30, 2021 before the market opens on August 10, 2021. The company will host a conference call at 8:30 a.m. Eastern Time on August 10, 2021, to provide a business update and discuss the financial results. Tuesday, August 10: 8:30 a.m. Eastern Time Domestic: (833) 979-2765 International: (343) 761-2590 Webcast Link: https://event.on24.com/wcc/r/3194348/D7BBD3D17DC6E8447B1781C07F60BE82 Conference ID: 4254409 About Marinus Pharmaceuticals Marinus Pharm

Orion obtains rights to commercialize both the oral and IV franchises of ganaxolone in Europe Collaboration supports mid-2022 European launch of oral ganaxolone for CDKL5 deficiency disorder, if approved; leverages Orion's expertise in rare orphan diseases, antiepileptics and European commercialization Marinus to receive €25 million (~$30 million) as an upfront fee and is eligible to receive up to €97 million (~$115 million) in R&D reimbursement, development and commercialization milestone payments, as well as tiered double-digit royalties on net sales in the European Economic Area, UK and Switzerland Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the